Why the study?
This study aimed to measure MR-proADM levels during the acute and recovery phases of STEMI and determine whether they were associated with adverse cardiac events after recovery.
Does the level of mid-regional proadrenomedullin (MR-proADM) during the acute phase of STEMI predict adverse cardiac events within 90 days?
Population
83 subjects with acute phase STEMI admitted to the intensive cardiac care unit
Comparison
MR-proADM levels on admission vs at day-30 follow-up
Design
Prospective study
Follow-up
90 days
Key result
Higher MR-proADM levels on hospital admission for acute STEMI were independently associated with adverse cardiac events at 90 days (adjusted OR 1.002; 95% CI 1.001-1.003; p=0.049).
Authors
Loading...
Acute MR-proADM levels were associated with 30- and 90-day events post-STEMI; leaves open incremental value for risk stratification.
Cohort (n=83)
Does the level of mid-regional proadrenomedullin (MR-proADM) during the acute phase of STEMI predict adverse cardiac events within 90 days?
Odds Ratio: 1.002 (95% CI 1.001–1.003)
p-value: p=0.049
High MR-proADM levels during the acute phase of STEMI and their change intensity are independent predictors of adverse cardiac events within 90 days.
Hartopo et al. (2022) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=83). Mid-regional proadrenomedullin (MR-proADM) level was evaluated on Composite of death, chronic heart failure, and hospital readmission of any cardiac causes at 90 days (adjusted OR 1.002, 95% CI 1.001-1.003, p=0.049). Higher MR-proADM levels on hospital admission for acute STEMI were independently associated with adverse cardiac events at 90 days (adjusted OR 1.002; 95% CI 1.001-1.003; p=0.049).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: